Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kinetics of antimicrobial activity.

B Vogelman, W A Craig

    The Journal of Pediatrics
    |May 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Standard antimicrobial testing is insufficient. Understanding the kinetics of antimicrobial action, including killing rates and post-antibiotic effects, is crucial for optimizing drug dosage regimens and improving treatment efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

    Antimicrobial agents and chemotherapy·2014
    Same author

    In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

    Antimicrobial agents and chemotherapy·2013
    Same author

    In vivo pharmacodynamics of new lipopeptide MX-2401.

    Antimicrobial agents and chemotherapy·2010
    Same author

    In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

    Antimicrobial agents and chemotherapy·2008
    Same author

    Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

    Antimicrobial agents and chemotherapy·2006
    Same author

    Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

    Antimicrobial agents and chemotherapy·2005

    Area of Science:

    • Pharmacology
    • Microbiology
    • Infectious Diseases

    Background:

    • Standard in vitro tests like minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) provide incomplete assessments of antimicrobial activity.
    • A comprehensive understanding requires evaluating bacterial killing rates, concentration-dependent effects, sub-MIC impacts, and post-antibiotic effects (PAE).

    Purpose of the Study:

    • To highlight the limitations of standard antimicrobial susceptibility testing.
    • To emphasize the importance of pharmacokinetic and pharmacodynamic (PK/PD) parameters in describing antimicrobial action.
    • To correlate antimicrobial kinetics with optimal dosing strategies in infection models.

    Main Methods:

    • Review of existing literature on antimicrobial kinetics and in vivo efficacy studies.

    Related Experiment Videos

  • Analysis of antimicrobial properties such as concentration-dependent vs. time-dependent killing.
  • Evaluation of post-antibiotic effects (PAE) for different antibiotic classes.
  • Comparison of efficacy for various dosing regimens in animal infection models.

    • Main Results:

    • Aminoglycosides show concentration-dependent killing and a significant PAE.
    • Beta-lactams exhibit time-dependent killing with minimal PAE, except against staphylococci.
    • Most bacteriostatic agents also demonstrate post-antibiotic growth suppression.
    • In vivo studies indicate beta-lactams are more effective with continuous dosing, while aminoglycosides are less sensitive to dosing frequency.

    Conclusions:

    • Antimicrobial activity assessment must extend beyond MIC/MBC to include kinetic parameters.
    • Understanding the kinetics of antimicrobial action is essential for designing optimal and effective antibiotic dosage regimens.
    • Kinetic profiling aids in predicting therapeutic success across different antibiotic classes and infection types.